ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
Launched by OPHTHOTECH CORPORATION · Dec 11, 2017
Trial Information
Current as of April 29, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of IPCV
- • Patients must have had 3 sequential Eylea injections within the previous 4 months
- Exclusion Criteria:
- • Intravitreal treatment in the study eye prior to screening, regardless of indication, except 3 prior injections of Eylea
- • History or evidence of severe cardiac disease
- • Any major surgical procedure within one month of trial entry
- • Subjects with a clinically significant laboratory value
- • Any treatment with an investigational agent in the past 60 days for any condition
- • Women who are pregnant or nursing
- • Known serious allergies to the fluorescein dye, ICG dye, iodine, povidone iodine, or to the components or formulation of either Zimura or Eylea
About Ophthotech Corporation
Ophthotech Corporation is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. With a focus on addressing unmet medical needs in conditions such as age-related macular degeneration and other vision-threatening disorders, Ophthotech is committed to advancing its proprietary drug candidates through rigorous clinical trials. The company's expertise in ophthalmology and its robust pipeline reflect a strong commitment to improving patient outcomes and enhancing the quality of life for individuals affected by debilitating eye diseases. Through strategic partnerships and a dedication to scientific excellence, Ophthotech aims to lead the way in transforming the landscape of retinal treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
'Aiea, Hawaii, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials